Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | IDE | P14735 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | HLCS | P50747 | 5/20 | 0.60 |
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12724896 | 1.00 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21524656 | 1.00 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL27414509 | 0.93 | TDP1 (0.66) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21958835 | 0.92 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL8146132 | 0.91 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378129 | 0.90 | TDP1 (0.66) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL319055 | 0.88 | TDP1 (0.67) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL31378083 | 0.88 | TDP1 (0.63) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14159597 | 0.87 | TDP1 (0.71) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21841844 | 0.87 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-03 | — | — | US | disclosed |
| US-9902985-B2 | Chemoenzymatic methods for synthesizing moenomycin analogs | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000860-A1 | USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD) | BCL6, BCL6B, EZH2 | TDP1 2409/4885MEN1 3905/4885ABL1 248/4885 |
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | TDP1 1798/4885MEN1 272/4885ABL1 2331/4885 |
| US-20190135796-A1 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | TDP1 2354/4885MEN1 1551/4885ABL1 375/4885 |
| US-20200039968-A9 | EZH2 INHIBITORS AND USES THEREOF | EZH2, EZH1, BMI1 | TDP1 2354/4885MEN1 1551/4885ABL1 375/4885 |
| US-20230339922-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | TDP1 1647/4885MEN1 4588/4885ABL1 5/4885 |
| US-10633371-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | TDP1 2354/4885MEN1 1551/4885ABL1 375/4885 |
| US-11236082-B2 | EZH2 inhibitors and uses thereof | EZH2, EZH1, BMI1 | TDP1 2226/4885MEN1 1860/4885ABL1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.